Shanghai Fosun Pharmaceutical (Group) Co.'s (HKG:2196) independently developed small molecule oral DPP-1 inhibitor, XH-S004, has been approved for clinical trials in China for the treatment of chronic obstructive pulmonary disease (COPD).
XH-S004 is also being trialed for the treatment of non-cystic fibrosis bronchiectasis, according to its Hong Kong bourse filing on Friday.
As of April, the Group had invested about 61 million yuan in the research and development of XH-S004.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。